Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric or Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06241469
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Who this might be right for
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Wu Jun 40
Testing effectiveness (Phase 2)Study completedNCT04053205
What this trial is testing

Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 76
Testing effectiveness (Phase 2)UnknownNCT04263870
What this trial is testing

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more
Sichuan University 36
Early research (Phase 1)Study completedNCT05327231
What this trial is testing

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Who this might be right for
Gastric Cancer
InxMed (Shanghai) Co., Ltd. 33
Not applicableActive Not RecruitingNCT05165264
What this trial is testing

Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Bristol-Myers Squibb 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT04396821
What this trial is testing

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerGastric CancerGastroesophageal-junction Cancer+1 more
Transcenta Therapeutics (Hangzhou) Co., Ltd. 150
Not applicableUnknownNCT04443036
What this trial is testing

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Who this might be right for
Gastric Carcinoma
China Medical University, China 44
Large-scale testing (Phase 3)UnknownNCT02934464
What this trial is testing

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Who this might be right for
Stomach Neoplasms
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 280
Testing effectiveness (Phase 2)Ended earlyNCT03840967
What this trial is testing

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Who this might be right for
Esophageal CancerGastric CancerAdenocarcinoma
Shadia Jalal, MD 14
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Large-scale testing (Phase 3)Study completedNCT04882241
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Merck Sharp & Dohme LLC 120
Testing effectiveness (Phase 2)UnknownNCT05994456
What this trial is testing

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University 24
Early research (Phase 1)UnknownNCT03276156
What this trial is testing

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Zhejiang Cancer Hospital 12
Large-scale testing (Phase 3)Looking for participantsNCT06731478
What this trial is testing

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 726
Large-scale testing (Phase 3)Not Yet RecruitingNCT06093425
What this trial is testing

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
Transcenta Therapeutics (Hangzhou) Co., Ltd. 820
Testing effectiveness (Phase 2)UnknownNCT04631757
What this trial is testing

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Large-scale testing (Phase 3)Ended earlyNCT01813253
What this trial is testing

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Kuhnil Pharmaceutical Co., Ltd. 400
Testing effectiveness (Phase 2)Ended earlyNCT04189445
What this trial is testing

Futibatinib in Patients With Specific FGFR Aberrations

Who this might be right for
Advanced or Metastatic Solid TumorAdvanced or Metastatic Gastric or Gastroesophageal CancerMyeloid or Lymphoid Neoplasms (MLN)
Taiho Oncology, Inc. 115
Early research (Phase 1)Not Yet RecruitingNCT06748872
What this trial is testing

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Who this might be right for
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more
Medigene AG 55
Not applicableApproved For MarketingNCT02065765
What this trial is testing

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerMetastatic Adenocarcinoma of the Gastroesophageal Junction
Eli Lilly and Company
Next Page